This article is more than 5 years old. Information may no longer be current.

Alphaeon acquires Lensar, partners with PhysIOL to commercialize trifocal IOL technology

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LAS VEGAS — Alphaeon has entered into a definitive agreement to acquire Lensar for an estimated $59 million in cash, stock and assumed debt, the company announced in a press release.

"We’re excited with the chance to join Alphaeon, and together leverage our proprietary platform technology to develop new clinical innovations benefiting physicians and patients alike," Nick Curtis, CEO of Lensar said in the release.

Alphaeon has also entered into a definitive agreement with PhysIOL to develop and commercialize a trifocal lens technology, which will be branded by Alphaeon, the company announced in a separate release.

The acquisition of Lensar, with its femtosecond laser technology, in combination with the partnership with PhysIOL, with its trifocal lens technology, will enable Alphaeon “to really go after dysfunctional lens syndrome as a category, and that fits right inside the Alphaeon mission,” Robert E. Grant, CEO of Alphaeon, told Healio.com/OSN at the American Academy of Ophthalmology annual meeting.